Atorvastatin Calcium Tablet, Film Coated
Product Images NDC 82804-054

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Atorvastatin Calcium (NDC 82804-054). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Chemical Structure)

Chemical structure of atorvastatin calcium dihydrate, showing its molecular components including fluorophenyl, phenyl, and hydroxy groups, and calcium ion complex with hydrate molecules.*

FDA Label Image

82804-054-30 (Container Label 20mg)

Atorvastatin Calcium 20 mg film-coated tablets label from Proficient Rx LP. The white, oval tablets are debossed with 'A5' on one side and plain on the other. The label includes quantity (#30 tablets), manufacturer (Recipharm Pharmaservices Pvt. Ltd., India), storage instructions, barcodes, and packaging details with NDC 82804-054-30.*

FDA Label Image

Figure 1.jpg (Figure1)

A line graph showing cumulative incidence (%) on the y-axis versus years on the x-axis up to 3.5 years. The graph compares two groups: Atorvastatin and Placebo, with Atorvastatin represented by a solid line and Placebo by a dashed line. The cumulative incidence rises more slowly for Atorvastatin than for Placebo over time. The graph includes a hazard ratio (HR=0.64) with confidence interval and a p-value of 0.0005 indicating statistical data comparison.*

FDA Label Image

Figure 2.jpg (Figure2)

A line graph showing the cumulative hazard percentage over time in years up to 5 years of follow-up, comparing Atorvastatin and Placebo groups. The graph illustrates time to first primary endpoint, with Atorvastatin represented by a solid line and Placebo by a dashed line, indicating a lower cumulative hazard in the Atorvastatin group.*

FDA Label Image

Figure 3.jpg (Figure3)

A line graph comparing the percentage of subjects experiencing a major cardiovascular event over five years between two doses of atorvastatin, 10 mg and 80 mg. Time to first major cardiovascular endpoint is shown on the x-axis (years), and subjects (%) experiencing the event on the y-axis. The graph includes hazard ratio and p-value statistics.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.